OptiPEA, the pain-relieving natural nutraceutical, could meet the needs of companies seeking a proven alternative to cannabidol (CBD).
CBD and products containing CBD have now been reclassified by the EU as ‘Novel Foods’ and require authorisation for use. As a result, there is uncertainty around their status in the supplements sector. There is also reluctance to include CBD and hemp-based ingredients in pain relief products as they frequently do not meet quality and regulatory standards, or the requirements of R&D departments.
However, OptiPEA by Netherlands-based Innexus Nutraceuticals offers a proven natural alternative that is available immediately. OptiPEA is a safe and reliable nutraceutical solution backed by over 60 years of research. It is formulated from palmitoylethanolamide (PEA), a naturally occurring bioactive lipid which has consistently been shown to deliver positive results without negative side effects1.
Innexus will showcase OptiPEA at Vitafoods Europe 2019 at the booth of its new distributor IMCD on Stand H64.
Samuel Zonneveld, CEO of Innexus, says: ‘With OptiPEA we offer companies the opportunity to benefit from the current worldwide interest in the endocannabinoid system. It also meets the rising demand for a safe solution for chronic pain, and the consumer trend toward branded, transparent and sustainable ingredients.’
He continues: ‘CBD has always been a ‘problem child’ of the nutraceuticals industry, due to its varying legal status around the world and ongoing regulatory issues. But when everyone else was focusing on CBD we had a clear vision for OptiPEA as a viable alternative. Its potential as a nutraceutical is almost unlimited and with the uncertainty around the status of CBD likely to continue, manufacturers can be reassured that there’s an effective alternative already available.’
Demand for nutraceutical pain relief solutions is on the rise, partly because of a desire to move away from opioids and the serious issues their misuse can cause2,3. PEA is a cannabimimetic, which means it mimics the process of CBD in the body. It could can even be considered a better alternative to hemp cannabinoid products because it is a single molecule and therefore much easier to measure into precise doses.
In addition, OptiPEA is produced sustainably from RSPO-certified palmitic acid and manufactured entirely in Europe using a patented GMP production process. It offers consistent quality and its origin is completely transparent and sustainable.
1 Mark R. Jones, Omar Viswanath, Jacquelin Peck, Alan D. KayeJatinder S. Gill, Thomas T. Simopoulos. ‘A Brief History of the Opioid Epidemic and Strategies for Pain Medicine’. Pain and Therapy: June 2018, Volume 7, Issue 1, pp 13–21
2 Mark D Neuman, Brian T Bateman, Hannah Wunsch. ‘Inappropriate opioid prescription after surgery’. The Lancet: April 13, 2019, Vol. 393, No. 10180, p1547–1557
3 Artukoglu BB, Beyer C, Zuloff-Shani A, Brener E, Bloch MH. ‘Efficacy of Palmitoylethanolamide for Pain: A Meta-Analysis’. Pain Physician: 2017 Jul;20(5):353-362